http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-2657532-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 |
| filingDate | 1976-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ef2adaa92348d66603393bf347d92b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a2ef09ab711f03d090c1712e069f27e |
| publicationDate | 1978-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-2657532-A1 |
| titleOfInvention | PHARMACEUTICAL PREPARATION |
| abstract | Pharmaceutical compsn. comprises L-Dopa (I) plus 1- 2-(5-methylpyrazol-3-yl)ethyl -phenyl-3,4-dehydropiperidine (II) or one of its physiologically innocuous acid addn. salts. (I) is well known for treatment of Parkinson's disease but large doses of it disturb cerebral metabolism of noradrenalin and serotonin. (II) has specific dopamine-stimulating activity in the CSN (esp. it stimulates supersensitive dopamine receptors) but does not influence dopamine transport in healthy neurons, so allows the dose of (I) to be reduced. (II) is known from DT 2060816 to have narcotic-potentiating activity. |
| priorityDate | 1976-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.